Serious bacterial infections are a major source of morbidity and mortality in HIV-infected children. The spectrum of disease is wide, and responsible organisms vary according to setting. The use of antibiotic prophylaxis and the emergence of multi-drug resistant bacteria necessitate examination of responsible organisms and their antibiotic susceptibility.
A retrospective cohort study of all HIV-positive pediatric admissions at an urban public sector hospital in Cape Town between January 2002 and June 2006 was conducted. Children between the ages of one month and nine years with laboratory confirmed HIV status, serious bacterial infection, and a hospital length of stay of 5 days or more, were eligible for inclusion. Organisms isolated from blood, urine, and cerebral spinal fluid cultures and their antimicrobial susceptibility were examined, and compared according to timing of isolation to distinguish nosocomial versus community-acquired. One hundred and forty-one children were identified (median age 1.2 years), 39% of whom were on antiretrovirals started before or during this hospitalization. Bacterial infections involved all organ systems, however pneumonia was most common (67%). S. pneumoniae and S. aureus were the most common gram positive and K. pneumoniae was the most common gram negative organism. K pneumoniae isolates were resistant to many first and second line antibiotics, and were all considered nosocomial. All S. aureus isolates were methicillin resistant, some of which were community-acquired.
Bacterial infections are an important source of co-morbidity in HIV-infected children in resource-limited settings. Clinicians should have a low threshold to initiate antibiotics in children requiring hospitalization. Broad-spectrum antibiotics should be used judiciously. Clinicians caring for HIV-infected children should be cognizant of the most common organisms affecting such children, and of their local antimicrobial susceptibilities, when treating empirically for serious bacterial infections.
Citation: Jaspan HB, Huang LC, Cotton MF, Whitelaw A, Myer L (2008) Bacterial Disease and Antimicrobial Susceptibility Patterns in HIV-Infected, Hospitalized Children: A Retrospective Cohort Study. PLoS ONE 3(9): e3260. https://doi.org/10.1371/journal.pone.0003260
Editor: Adam J. Ratner, Columbia University, United States of America
Received: June 7, 2008; Accepted: September 1, 2008; Published: September 24, 2008
Copyright: © 2008 Jaspan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: LCH was supported in part by the Palo Alto/University Rotary Club, the Waterfront Rotary Club of Cape Town, and the Rotary Foundation, through the Ambassadorial Scholar program, none of whom had any role in the design, conduct, analysis, interpretation and preparation of the research or manuscript.
Competing interests: The authors have declared that no competing interests exist.
Bacterial infections are a major source of morbidity and mortality in HIV- infected children, causing . a wide spectrum of diseases, many of which are included in the WHO and CDC staging systems,  In an early USA study predating both trimethoprim-sulfamethoxazole (TMP-SMX) and antiretroviral therapy (ART), there were 160 episodes of minor and 48 serious bacterial infections (SBI) per 100 patient-years in HIV-infected children, demonstrating the extremely high burden of bacterial morbidity. A similar study performed after the introduction of TMP-SMX and zidovudine monotherapy documented a two-year SBI rate of 45% among children receiving TMP-SMX.. In a randomized controlled trial of TMP-SMX prophylaxis for HIV-infected children in Zambia, the SBI admission rate was 19 per 100 child-years in the TMP-SMX group and 29 in the placebo group (P = 0.09), and the cumulative two-year probability of dying in hospital from SBI (predominantly pneumonia) was 7% on TMP-SMX and 12% on placebo (P = 0.08). Thus, data from varied settings documented high rates of SBI in children and a protective effect of TMP-SMX.
Since the widespread availability of antiretroviral therapy (ART), there has been a marked decrease in the morbidity and mortality of bacterial infections in both resource rich and resource limited settings , . In the USA, pneumonia is still the most common bacterial infection in HIV-infected children on ART, however, in comparison with the pr-ART era, the incidence has decreased from 11 to 2 events per 100 person years. In a Californian cohort, bacterial infections accounted for 60 hospitalizations for 64 children in 1994, versus only 8 for 101 children in 2001. The hospitalization rate for SBI was only 14.2 per 100 person years for a Thai cohort of children on ART. Nevertheless, bacterial infections remained the most common reason for hospitalization.
HIV-infected children have a greater risk of bacterial infections than their HIV-negative counterparts, and these infections are more invasive, more likely to disseminate, and have worse outcome in HIV-infected children.– Also, HIV-infected children often have multiple diagnoses and polymicrobial infections.,  All organ systems can be involved by bacterial infections, and concomitant bacteraemia is common. Abscess formation in internal organs and skin can also occur. Otitis media (OM), acute sinusitis and mastoiditis are also common. By far the most frequent cause of bacterial morbidity in all HIV-infected children is pneumonia, both with and without TMP-SMX prophylaxis.
The emergence of antimicrobial resistant organisms is a global problem, not restricted to children with HIV. However, the widespread use of TMP-SMX for prophylaxis may exacerbate antimicrobial resistance. In a South African study, only four of 26 S. pneumoniae from HIV-infected children with community acquired pneumonia were sensitive to TMP-SMX. Resistance was unaffected by TMP-SMX prophylaxis, arguing that resistance may be firmly established in the community. The antimicrobial resistance patterns from blood cultures from HIV infected and uninfected children have been compared in only a few settings. The resistance of both S. pneumoniae and S. aureus to TMP-SMX was significantly higher in the HIV-infected group's isolates in Soweto . In three African studies, almost 15% of the isolates from HIV-infected children were multiply resistant E. coli or Methicillin resistant staphylococcus aureus (MRSA). – However, in the Ugandan children, organisms from HIV-infected children were either more sensitive or had the same profile as uninfected children. Therefore it is unclear how widespread antimicrobial resistance is in HIV-infected children.
We sought to evaluate the spectrum of bacterial infection, causative organisms, and antibiotic resistance patterns of an inpatient cohort of HIV-infected children.
We conducted a retrospective cohort study of all HIV-positive pediatric admissions to a Pediatric ward in an urban public sector hospital in Cape Town between January 2002 and June 2006. Over 50% of all admissions are HIV-infected. The referral population is a largely black African population living in rapidly growing settlements with residents of predominantly low socioeconomic status. Data were collected from paper charts and computer records. Where more than one hospitalization per patient occurred, only the first was examined.
Children between one month and nine years of age with laboratory confirmed HIV-infection, SBI and hospitalization for 5 or more days, were eligible for inclusion.
Description of investigations
The following were considered SBI: bacterial sepsis, bacterial pneumonia, urinary tract infection, and/or meningitis. For bacterial sepsis, children had organisms identified on blood culture. Diagnosis of bacterial pneumonia was made by clinical findings, laboratory results including high white blood cell count with neutrophil predominance, lobar consolidation on chest radiograph, and blood cultures when available. For meningitis, either an organism was isolated from cerebrospinal fluid or the chemistry and cell counts were suggestive of bacterial infection. Coagulase negative staphylococcus only included as a pathogen if isolated from more than one culture or from a patient with indwelling invasive lines. All S. aureus isolates were considered pathogenic, as the patients were ill. An infection was considered community acquired if symptomatic at admission or if cultures taken at or before 48 hours after admission were positive. If positive cultures or new symptoms appeared after 48 hours, the infection was considered nosocomial or hospital acquired .
Clinical specimens submitted for bacterial culture were inoculated into appropriate media depending on the nature of the specimen. Organisms were identified by standard biochemical and/or serological methods. Antimicrobial susceptibility testing was done by the Kirby-Bauer disc diffusion technique, and MICs (if necessary) were performed using E-tests. Susceptibilities were not available for all specimens from 2002–2003. Therefore, susceptibilities represent more recent specimens.
One hundred and forty-one children met inclusion criteria. The median age was 1.2 years (IQR 0.5–2.3) and 65 (46%) were female (table 1). The median weight on admission was 6.7 kg (IQR 4.7–9.6)), 16 (11.4%) with a diagnosis of marasmus and a further 27 (19%) labeled as failure to thrive.
Approximately one third of children received ART(n = 55). However, the median time on ART was only 6 days (IQR -8–35), and many were started during this hospitalization. There were 40 children on tuberculosis treatment; some children were receiving both ART and TB treatment (n = 16; 11.3%). The median CD4 percentage was 17.2% (IQR 9.7–22.7), with a median absolute CD4 count of 509 cells/mm3 (IQR 244–759). The median hospital length of stay was 13 days (IQR 6–34 days). There were 13 deaths in hospital with the remainder being discharged.
Spectrum of Disease
A lower respiratory tract infection was diagnosed in 95 (67%) of the children, while 74 (53%) had bacterial sepsis. The most prevalent bacterial infections in this cohort of hospitalized children were pneumonia and sepsis (Table 1). However, most other organ systems were affected, including the central nervous system (meningitis), lung, mastoid, bone and joints. A high proportion of patients with pneumonia, meningitis, and urinary tract infection had concomitant bacteremia. Mycobacterium tuberculosis was a frequent concomitant infection. Eight deaths had dual diagnoses of sepsis and pneumonia, and one had both sepsis and a UTI.
The relative frequencies of specific bacterial isolates from blood, urine and CSF cultures of HIV-infected children are shown in table 2 (excluding mycobacteria). The most common pathogen isolated from blood was S. pneumoniae followed by S aureus. The most common gram negative organism was K. pneumoniae. All K. pneumoniae isolates were from blood cultures taken more than two days into the admission, implying a nosocomial origin. In contrast, all but two S pneumoniae from blood culture were within two days of admission, therefore probably community acquired. The organisms most frequently present when the outcome was fatal were S aureus (n = 3, all MRSA), Coagulase negative staphylococcus (n = 3) and K pneumoniae (n = 3). Five of the 13 children who died grew multiple pathogenic organisms in blood or urine.
The antimicrobial susceptibility patterns of each of the more prevalent organisms are shown in table 3. S. pneumoniae and H. influenza isolates were generally highly susceptible, whereas the majority of the K. pneumoniae isolates, most likely nosocomial, were highly resistant. All K. pneumoniae isolates were extended spectrum beta-lactamase producing; the only single antibiotic to which all K. pneumoniae isolates were susceptible was Meropenem. S. aureus whether community-acquired or nosocomial, was often resistant to TMP-SMX, and clindamycin, both frequently used antibiotics for resistant staphylococci. . Although community-acquired non-typhoid salmonella (NTS) were susceptible to first-line antibiotics such as ampicillin, the more frequently hospital-acquired organisms were more resistant. MRSA was isolated from a third of the blood cultures of children who died, as was K. pneumoniae, therefore resistant organisms were possibly responsible for a relatively high proportion of the mortality, and appropriate empiric therapy was not used.
In this cohort of hospitalized HIV-infected children, pneumonia was the most common SBI resulting in hospitalization. There was frequent coincident bacteremia. This is consistent with other HIV-infected pediatric cohorts described from both developing and developed settings, . The relative prevalence of most bacterial pathogens is similar to that of HIV-uninfected children. In a large Kenyan study S. pneumoniae, H. influenzae, NTS, and E. coli were more common in HIV-infected children . These organisms were commonly seen in malnourished children in the pre-HIV era. S. pneumoniae is the most common organism in other cohorts, with S. aureus, Salmonella species, and Enterobacteriaceae occurring frequently , , , . P. aeruginosa is also seen occasionally. The proportion of H influenzae is influenced by the introduction of the H. influenzae type B (Hib) vaccine, in 1999 in South Africa.
Bacteria that were assumed to be predominantly community acquired were generally susceptible to first line or narrow spectrum antibiotics (those that target generally only one class of bacteria). This included the S. pneumoniae isolates. In other settings, multi-drug resistant S. pneumoniae were increasing in frequency before introduction of the pneumococcal conjugate vaccine , . In children with community acquired pneumonias in Soweto, South Africa, 50% of the S. pneumoniae isolates from the HIV-infected children were penicillin resistant versus 23% of the HIV-negative children's isolates. The community-acquired S. aureus isolates were, however, all MRSA. The empiric treatment of community acquired bacterial infections in HIV-infected children in resource limited settings should bear in mind the antimicrobial susceptibility patterns of the region. Penicillin and ampicillin are effective against most penicillin-non-susceptible pneumococcal isolates in the case of isolated respiratory tract infections. The clinician must consider viral, fungal, and mycobacterial infections in the differential diagnosis of bacterial infections and treat accordingly.
The high proportion of K. pneumoniae resistant to third generation cephalosporin is highly concerning, particularly since all these infections were acquired after two days in hospital, and therefore probably hospital-acquired. Highly resistant organisms have been described from a similar setting , and is likely due to extended spectrum beta lactamase production. Since not all K. pneumoniae isolates were susceptible to piperacillin-tazobactam or amikacin, clinicians should consider empiric carbapenems for suspected hospital-acquired sepsis.
Nosocomial infections are more common in HIV-infected than in uninfected adults, with the most frequently isolated bacterial pathogens being S. aureus and P. aeruginosa, a high proportion of which are methicillin resistant . Nosocomial infections in HIV-infected adults have a high mortality. There are few data on nosocomial bacterial infections in HIV-infected children. In a cohort of children hospitalized with TB, nosocomial infections were more common in HIV-infected patients, and more frequently fatal . Although our data do not reflect the overall prevalence of nosocomial infections in hospitalized HIV-infected children due to our study design, the data may represent common resistance patterns of these organisms.
The most effective public health approach to improving infectious disease burden is vaccination. Effective vaccines are licensed for Hib and S. pneumoniae. Both are polysaccharide protein conjugate vaccines. The Hib vaccine is now widely available including in developing countries. Although the estimated efficacy of the Hib vaccine is decreased and the risk for vaccine failure increased in HIV-infected children,,  the introduction of Hib vaccine into countries with high HIV prevalence has greatly decreased Hib disease burden. In 2000, a pneumococcal conjugate vaccine (PCV) was licensed in the USA. Although PCV is less immunogenic in HIV-infected children than non-infected children, this also seems to improve in children receiving ART. A similar 9-valent PCV has been extensively studied in South Africa, and similar efficacy is seen in these HIV-infected infants. Unfortunately, PCV is not widely accessible to children in less resourced countries, and its access should become a global priority.
These data confirm that pneumonia is the most common SBI in HIV-infected children, but with a wide spectrum of presentation. The predominance of MRSA is alarming. The high proportion of nosocomially acquired highly resistant K. pneumoniae, suggest that infection control practices should be implemented to avoid the spread of antibiotic resistance. While overuse of broad-spectrum antibiotics should be avoided, judicious limited use is indicated for suspected nosocomial sepsis.
The limitations of these data are that they are retrospective and therefore incomplete. In addition, the isolation of organisms is dependant on adequate blood volumes and rapid transport to the microbiology laboratory, both of which may have been limited in the setting of sick, malnourished children in a resource-limited hospital. Our findings may not be generalizable to other better resourced settings such as those with more nursing staff, and less ward crowding, or where all HIV-infected children are on ART.
The authors acknowledge the G25 ward staff and medical records at Groote Schuur Hospital.
Conceived and designed the experiments: HBJ. Performed the experiments: LCH. Analyzed the data: HBJ AW LM. Wrote the paper: HBJ MC. Provided clinical expertise: HBJ. Performed the data collection, and some statistical analysis: LCH. Performed literature review: MFC. Contributed to the laboratory methods and interpretation: AW. Revised the manuscript: MFC LM. Supervised study design and statistical analysis: LM.
- 1. CDC (1987) Classification system for human immunodeficiency virus (HIV) infection in children under 13 years of age. MMWR 36: 225–230.
- 2. World Health Organisation (2006) Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access
- 3. Mofenson L, Nugent R, Rigauperez J (1991) Serious Bacterial-Infections in Hiv-Infected Children in A Clinical-Trial of Intravenous Immunoglobulin. Pediatric Research 29: A179.
- 4. Spector SA, Gelber RD, Mcgrath N, Wara D, Barzilai A, et al. (1994) Controlled Trial of Intravenous Immune Globulin for the Prevention of Serious Bacterial-Infections in Children Receiving Zidovudine for Advanced Human-Immunodeficiency-Virus Infection. New England Journal of Medicine 331: 1181–1187.
- 5. Mulenga V, Ford D, Walker AS, Mwenya D, Mwansa J, et al. (2007) Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children. Aids 21: 77–84.
- 6. Nesheim SR, Kapogiannis BG, Soe MM, Sullivan KM, Abrams E, et al. (2007) Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004. Pediatrics 120: 100–109.
- 7. Kapogiannis BG, Soe MM, Nesheim SR, Sullivan KM, Abrams E, et al. (2008) Trends in bacteremia in the pre- and post-highly active antiretroviral therapy era among HIV-infected children in the US Perinatal AIDS Collaborative Transmission Study (1986-2004). Pediatrics 121: e1229–e1239.
- 8. Gona P, Van Dyke RB, Williams PL, Dankner WM, Chernoff MC, et al. (2006) Incidence of opportunistic and other infections in HIV-infected children in the HAART era. Jama-Journal of the American Medical Association 296: 292–300.
- 9. Viani RM, Araneta MRG, Deville JG, Spector SA (2004) Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clinical Infectious Diseases 39: 725–731.
- 10. Puthanakit T, Aurpibul L, Oberdorfer P, Akarathum N, Kanjananit S, et al. (2007) Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy. Clinical Infectious Diseases 44: 599–604.
- 11. McNally LM, Jeena PM, Gajee K, Thula SA, Sturm AW, et al. (2007) Effect of age, polymicrobial disease,, and maternal HIV status on treatment response and cause of severe pneumonia in South African children: a prospective descriptive study. Lancet 369: 1440–1451.
- 12. Meyers TM, Pettifor JM, Gray GE, Crewe-Brown H, Galpin JS (2000) Pediatric admissions with human immunodeficiency virus infection at a regional hospital in Soweto, South Africa. Journal of Tropical Pediatrics 46: 224–230.
- 13. Zar HJ, Hanslo D, Tannenbaum E, Klein M, Argent A, Eley B, Burgess J, Magnus K, Bateman ED, Hussey G (2001) Aetiology and outcome of pneumonia in human immunodeficiency virus-infected children hospitalized in South Africa. Acta Paediatrica 90: 119–125.
- 14. Madhi SA, Petersen K, Madhi A, Khoosal M, Klugman KP (2000) Increased Disease Burden and Antibiotic Resistance of Bacteria Causing Severe Community-Acquired Lower Respiratory Tract Infections in Human Immunodeficiency Virus Type 1-Infected Children. Clinical Infectious Diseases 31: 170–176.
- 15. Cotton M, Wasserman E, Smit J, Whitelaw A, Zar HJ (2008) High incidence of antimicrobial resistant organisms including extended spectrum beta-lactamase producing Enterobacteriaceae and methicillin-producing Staphylococcus aureus in nasopharyngeal and blood isolates of HIV-infected children from Cape Town, South Africa. PLOS Medicine.
- 16. Bachou H, Tylleskar T, Kaddu-Mulindwa DH, Tumwine JK (2006) Bacteraemia among severely malnourished children infected and uninfected with the human immunodeficiency virus-1 in Kampala, Uganda. Bmc Infectious Diseases 6:
- 17. Garner J, Jarvis W, Emori T, Horan T, Hughes J, Jarvis W (1988) CDC definitions for nosocomial infections. American Journal of Infection Control 16: 28–40.
- 18. Berkley J, Lowe B, Mwangi I, Williams T, Bauni E, et al. (2005) Bacteremia among children Admitted to a Rural Hospital in Kenya. New England Journal of Medicine 352: 39–47.
- 19. Winters M, Patrick D, Marra F, Buxton J, Chong M, Isaac-Renton J (2008) Epidemiology of invasive pneumococcal disease in BC during the introduction of conjugated pneumococcal vaccine. Canadian Journal of Public Health 99: 57–61.
- 20. Pletz M, Maus U, Krug N, Welte T, Lode H (2008) Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. International Journal of Antimicrobial Agents March 29 Epub ahead of print.
- 21. Franzetti F, Grassini A, Degl'innocenti M, Bandera A, Gazzola L, et al. (2006) Nosocomial bacterial pneumonia in HIV-infected patients: risk factors for adverse outcome and implications for rational empiric antibiotic therapy. Infection 34: 9–16.
- 22. Robinson A, Nel E, Donald P, Schaaf H (2007) SA Family Practice 49: 14.
- 23. Madhi SA, Kuwanda L, Saarinen L, Cutland C, Mothupi R, et al. (2005) Immunogenicity and effectiveness of Haemophilus influenzae type b conjugate vaccine in HIV infected and uninfected African children. Vaccine 23: 5517–5525.
- 24. Madhi SA, Petersen K, Khoosal M, Huebner RE, Mbelle N, et al. (2002) Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatric Infectious Disease Journal 21: 315–321.
- 25. von Gottberg A, de Gouveia L, Madhi SA, du Plessis M, Quan V, et al. (2006) Impact of conjugate Haemophilus influenzae type b (Hib) vaccine introduction in South Africa. Bulletin of the World Health Organization 84: 811–818.
- 26. King J, Vink P, Farley J, Parks M, Smilie M, et al. (1996) Safety and immunogenicity of 3 doses of a 5-valent pneumococcal conjugate vaccine (PCV) in HIV and non-HIV-infected children <2 yrs of age. Pediatric Research 39: 1037.
- 27. Abzug MJ, Pelton SI, Song LY, Fenton T, Levin MJ, et al. (2006) Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatric Infectious Disease Journal 25: 920–929.
- 28. Madhi SA, Adrian P, Kuwanda L, Jassat W, Jones S, et al. (2007) Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 25: 2451–2457.